These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 22770604)

  • 21. Taking immunogenicity assessment of therapeutic proteins to the next level.
    Büttel IC; Chamberlain P; Chowers Y; Ehmann F; Greinacher A; Jefferis R; Kramer D; Kropshofer H; Lloyd P; Lubiniecki A; Krause R; Mire-Sluis A; Platts-Mills T; Ragheb JA; Reipert BM; Schellekens H; Seitz R; Stas P; Subramanyam M; Thorpe R; Trouvin JH; Weise M; Windisch J; Schneider CK
    Biologicals; 2011 Mar; 39(2):100-9. PubMed ID: 21353596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products.
    Mire-Sluis AR; Barrett YC; Devanarayan V; Koren E; Liu H; Maia M; Parish T; Scott G; Shankar G; Shores E; Swanson SJ; Taniguchi G; Wierda D; Zuckerman LA
    J Immunol Methods; 2004 Jun; 289(1-2):1-16. PubMed ID: 15251407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating and Mitigating the Immunogenicity of Therapeutic Proteins.
    Sauna ZE; Lagassé D; Pedras-Vasconcelos J; Golding B; Rosenberg AS
    Trends Biotechnol; 2018 Oct; 36(10):1068-1084. PubMed ID: 29908714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of therapeutic proteins: influence of aggregation.
    Ratanji KD; Derrick JP; Dearman RJ; Kimber I
    J Immunotoxicol; 2014; 11(2):99-109. PubMed ID: 23919460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance.
    Song S; Yang L; Trepicchio WL; Wyant T
    J Immunol Res; 2016; 2016():3072586. PubMed ID: 27340678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity of Protein Pharmaceuticals.
    Dingman R; Balu-Iyer SV
    J Pharm Sci; 2019 May; 108(5):1637-1654. PubMed ID: 30599169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In silico methods for design of biological therapeutics.
    Roy A; Nair S; Sen N; Soni N; Madhusudhan MS
    Methods; 2017 Dec; 131():33-65. PubMed ID: 28958951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity in Protein and Peptide Based-Therapeutics: An Overview.
    Fernandez L; Bustos RH; Zapata C; Garcia J; Jauregui E; Ashraf GM
    Curr Protein Pept Sci; 2018; 19(10):958-971. PubMed ID: 28847291
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Cohen S; Chung S
    Bioanalysis; 2021 Jul; 13(13):1071-1081. PubMed ID: 34124935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Strategies for preclinical immunogenicity assessment of protein therapeutics.
    Stas P; Lasters I
    IDrugs; 2009 Mar; 12(3):169-73. PubMed ID: 19333897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protein particles: what we know and what we do not know.
    Ripple DC; Dimitrova MN
    J Pharm Sci; 2012 Oct; 101(10):3568-79. PubMed ID: 22736521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent Advances in Assessing Immunogenicity of Therapeutic Proteins: Impact on Biotherapeutic Development.
    Lu Y; Khawli LA; Purushothama S; Theil FP; Partridge MA
    J Immunol Res; 2016; 2016():8141269. PubMed ID: 27642612
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes.
    Krishna M; Nadler SG
    Front Immunol; 2016; 7():21. PubMed ID: 26870037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TCPro: an In Silico Risk Assessment Tool for Biotherapeutic Protein Immunogenicity.
    Yogurtcu ON; Sauna ZE; McGill JR; Tegenge MA; Yang H
    AAPS J; 2019 Aug; 21(5):96. PubMed ID: 31376048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minimizing the immunogenicity of protein therapeutics.
    Chirino AJ; Ary ML; Marshall SA
    Drug Discov Today; 2004 Jan; 9(2):82-90. PubMed ID: 15012932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coupling of aggregation and immunogenicity in biotherapeutics: T- and B-cell immune epitopes may contain aggregation-prone regions.
    Kumar S; Singh SK; Wang X; Rup B; Gill D
    Pharm Res; 2011 May; 28(5):949-61. PubMed ID: 21437790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonclinical immunogenicity risk assessment of therapeutic proteins.
    Tourdot S; Hickling TP
    Bioanalysis; 2019 Sep; 11(17):1631-1643. PubMed ID: 31208200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Industry experiences with immune-mediated findings in biotherapeutic nonclinical toxicology studies.
    MacLachlan TK; Kronenberg S; Marshall N; Andrews L; Berens SJ; Brouta F; Fogal B; Freebern W; Herzyk D; Kamperschroer C; Kiessling A; Schneidkraut M; Maier C
    Regul Toxicol Pharmacol; 2021 Feb; 119():104825. PubMed ID: 33220389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality.
    Hock MB; Thudium KE; Carrasco-Triguero M; Schwabe NF
    AAPS J; 2015 Jan; 17(1):35-43. PubMed ID: 25380723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity of therapeutics: a matter of efficacy and safety.
    Nechansky A; Kircheis R
    Expert Opin Drug Discov; 2010 Nov; 5(11):1067-79. PubMed ID: 22827745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.